Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health

April B M Grudell, Michael Camilleri, Kim L. Jensen, Amy E. Foxx-Orenstein, Duane D. Burton, Michael D. Ryks, Kari L. Baxter, Donna S. Cox, George E. Dukes, Dennis L. Kelleher, Alan R. Zinsmeister

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

β3-Adrenoceptors (β3-AR) are expressed by cholinergic myenteric neurons and β3-AR agonists are effective in experimental models of diarrhea. Our aim was to explore the effects of a β3-AR agonist, solabegron, on gastrointestinal transit, safety, bowel function, plasma somatostatin, and solabegron pharmacokinetics (PK) following single and multiple doses. In a single-center, double-blind, parallel-group trial, 36 healthy volunteers were randomized to oral solabegron (50 or 200 mg twice daily) or placebo. Transit was measured by a validated method (99mTc-labeled egg meal and 111In charcoal delivered to the colon via delayed-release capsule). Stool frequency, form, and ease of passage were measured on a validated daily diary; plasma somatostatin by radioimmunoassay and plasma solabegron and its active metabolite by validated liquid chromatography-tandem mass spectroscopy analysis followed by PK analysis using noncompartmental methods. There were no overall or dose-related effects of solabegron on gastric, small bowel, or colonic transit, plasma somatostatin levels, stool frequency, form, or ease of passage in healthy volunteers. Solabegron and active metabolite exposures (area under the curve and maximum serum concentration) at both dose levels were consistent with PK at similar doses in previous phase I studies. We concluded that 7 days of the β3-AR agonist, solabegron, 50 or 200 mg twice daily, did not significantly alter gastrointestinal or colonic transit or bowel function. In this study, medication was generally well tolerated with few adverse events reported and no clinically significant changes in vital signs observed. Further studies on clinical efficacy, visceral sensitivity, and gastrointestinal transit are required in irritable bowel syndrome patients.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume294
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Gastrointestinal Transit
Adrenergic Agonists
Somatostatin
Health Status
Adrenergic Receptors
Pharmacokinetics
Healthy Volunteers
Cholinergic Neurons
Vital Signs
Irritable Bowel Syndrome
Charcoal
solabegron
Liquid Chromatography
Area Under Curve
Capsules
Radioimmunoassay
Ovum
Meals
Diarrhea
Mass Spectrometry

Keywords

  • Colon
  • Motility
  • Pharmacokinetics

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology (medical)
  • Physiology
  • Hepatology

Cite this

Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. / Grudell, April B M; Camilleri, Michael; Jensen, Kim L.; Foxx-Orenstein, Amy E.; Burton, Duane D.; Ryks, Michael D.; Baxter, Kari L.; Cox, Donna S.; Dukes, George E.; Kelleher, Dennis L.; Zinsmeister, Alan R.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 294, No. 5, 05.2008.

Research output: Contribution to journalArticle

Grudell, April B M ; Camilleri, Michael ; Jensen, Kim L. ; Foxx-Orenstein, Amy E. ; Burton, Duane D. ; Ryks, Michael D. ; Baxter, Kari L. ; Cox, Donna S. ; Dukes, George E. ; Kelleher, Dennis L. ; Zinsmeister, Alan R. / Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2008 ; Vol. 294, No. 5.
@article{5879865097734e128fde3655c22de6c1,
title = "Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health",
abstract = "β3-Adrenoceptors (β3-AR) are expressed by cholinergic myenteric neurons and β3-AR agonists are effective in experimental models of diarrhea. Our aim was to explore the effects of a β3-AR agonist, solabegron, on gastrointestinal transit, safety, bowel function, plasma somatostatin, and solabegron pharmacokinetics (PK) following single and multiple doses. In a single-center, double-blind, parallel-group trial, 36 healthy volunteers were randomized to oral solabegron (50 or 200 mg twice daily) or placebo. Transit was measured by a validated method (99mTc-labeled egg meal and 111In charcoal delivered to the colon via delayed-release capsule). Stool frequency, form, and ease of passage were measured on a validated daily diary; plasma somatostatin by radioimmunoassay and plasma solabegron and its active metabolite by validated liquid chromatography-tandem mass spectroscopy analysis followed by PK analysis using noncompartmental methods. There were no overall or dose-related effects of solabegron on gastric, small bowel, or colonic transit, plasma somatostatin levels, stool frequency, form, or ease of passage in healthy volunteers. Solabegron and active metabolite exposures (area under the curve and maximum serum concentration) at both dose levels were consistent with PK at similar doses in previous phase I studies. We concluded that 7 days of the β3-AR agonist, solabegron, 50 or 200 mg twice daily, did not significantly alter gastrointestinal or colonic transit or bowel function. In this study, medication was generally well tolerated with few adverse events reported and no clinically significant changes in vital signs observed. Further studies on clinical efficacy, visceral sensitivity, and gastrointestinal transit are required in irritable bowel syndrome patients.",
keywords = "Colon, Motility, Pharmacokinetics",
author = "Grudell, {April B M} and Michael Camilleri and Jensen, {Kim L.} and Foxx-Orenstein, {Amy E.} and Burton, {Duane D.} and Ryks, {Michael D.} and Baxter, {Kari L.} and Cox, {Donna S.} and Dukes, {George E.} and Kelleher, {Dennis L.} and Zinsmeister, {Alan R.}",
year = "2008",
month = "5",
doi = "10.1152/ajpgi.00051.2008",
language = "English (US)",
volume = "294",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health

AU - Grudell, April B M

AU - Camilleri, Michael

AU - Jensen, Kim L.

AU - Foxx-Orenstein, Amy E.

AU - Burton, Duane D.

AU - Ryks, Michael D.

AU - Baxter, Kari L.

AU - Cox, Donna S.

AU - Dukes, George E.

AU - Kelleher, Dennis L.

AU - Zinsmeister, Alan R.

PY - 2008/5

Y1 - 2008/5

N2 - β3-Adrenoceptors (β3-AR) are expressed by cholinergic myenteric neurons and β3-AR agonists are effective in experimental models of diarrhea. Our aim was to explore the effects of a β3-AR agonist, solabegron, on gastrointestinal transit, safety, bowel function, plasma somatostatin, and solabegron pharmacokinetics (PK) following single and multiple doses. In a single-center, double-blind, parallel-group trial, 36 healthy volunteers were randomized to oral solabegron (50 or 200 mg twice daily) or placebo. Transit was measured by a validated method (99mTc-labeled egg meal and 111In charcoal delivered to the colon via delayed-release capsule). Stool frequency, form, and ease of passage were measured on a validated daily diary; plasma somatostatin by radioimmunoassay and plasma solabegron and its active metabolite by validated liquid chromatography-tandem mass spectroscopy analysis followed by PK analysis using noncompartmental methods. There were no overall or dose-related effects of solabegron on gastric, small bowel, or colonic transit, plasma somatostatin levels, stool frequency, form, or ease of passage in healthy volunteers. Solabegron and active metabolite exposures (area under the curve and maximum serum concentration) at both dose levels were consistent with PK at similar doses in previous phase I studies. We concluded that 7 days of the β3-AR agonist, solabegron, 50 or 200 mg twice daily, did not significantly alter gastrointestinal or colonic transit or bowel function. In this study, medication was generally well tolerated with few adverse events reported and no clinically significant changes in vital signs observed. Further studies on clinical efficacy, visceral sensitivity, and gastrointestinal transit are required in irritable bowel syndrome patients.

AB - β3-Adrenoceptors (β3-AR) are expressed by cholinergic myenteric neurons and β3-AR agonists are effective in experimental models of diarrhea. Our aim was to explore the effects of a β3-AR agonist, solabegron, on gastrointestinal transit, safety, bowel function, plasma somatostatin, and solabegron pharmacokinetics (PK) following single and multiple doses. In a single-center, double-blind, parallel-group trial, 36 healthy volunteers were randomized to oral solabegron (50 or 200 mg twice daily) or placebo. Transit was measured by a validated method (99mTc-labeled egg meal and 111In charcoal delivered to the colon via delayed-release capsule). Stool frequency, form, and ease of passage were measured on a validated daily diary; plasma somatostatin by radioimmunoassay and plasma solabegron and its active metabolite by validated liquid chromatography-tandem mass spectroscopy analysis followed by PK analysis using noncompartmental methods. There were no overall or dose-related effects of solabegron on gastric, small bowel, or colonic transit, plasma somatostatin levels, stool frequency, form, or ease of passage in healthy volunteers. Solabegron and active metabolite exposures (area under the curve and maximum serum concentration) at both dose levels were consistent with PK at similar doses in previous phase I studies. We concluded that 7 days of the β3-AR agonist, solabegron, 50 or 200 mg twice daily, did not significantly alter gastrointestinal or colonic transit or bowel function. In this study, medication was generally well tolerated with few adverse events reported and no clinically significant changes in vital signs observed. Further studies on clinical efficacy, visceral sensitivity, and gastrointestinal transit are required in irritable bowel syndrome patients.

KW - Colon

KW - Motility

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=45849142177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849142177&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00051.2008

DO - 10.1152/ajpgi.00051.2008

M3 - Article

C2 - 18372395

AN - SCOPUS:45849142177

VL - 294

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5

ER -